Momordica charantia and metabolic regulation in the complementary integrative treatment of Diabetes Mellitus: An integrative review
DOI:
https://doi.org/10.33448/rsd-v13i5.45814Keywords:
Diabetes Mellitus; Complementary therapies; Momordica charantia.Abstract
Diabetes Mellitus is a chronic non-communicable disease manifested, above all, by the elevation of serum glycemia, and its treatment consists of lifestyle changes combined with pharmacological therapies. From this perspective, complementary integrative treatments have been evaluated as complementary strategies in glycemic control, with Momordica charantia standing out for its hypoglycemic effects. That said, the present study aimed to identify the effects of Momordica charantia linked to hypoglycemia and systemic metabolic regulation as an adjuvant complementary therapy for Diabetes Mellitus. The review was carried out in the PubMed, Medline and ScienceDirect databases using the DeCS: “Momordica charantia” and “Diabetes Mellitus”, linked by the Boolean operator “AND”, resulting in 25 articles for analysis. The studies report satisfactory results regarding the hypoglycemic effects of Momordica charantia through varied mechanisms, such as stimulating the use of glucose, activating GLP-1, suppressing enzymes involved in gluconeogenic pathways, inhibiting intestinal uptake, as well as improving sensitivity. insulin and decreased lipid accumulation in the liver. In addition to its hypoglycemic effect, research carried out with diabetic mice also reports possible renal, hepatic and anti-inflammatory benefits. Furthermore, it was observed that Momordica charantia has compounds that help balance metabolism and can be considered as a therapeutic adjuvant for Diabetes Mellitus. However, more studies are still needed to identify more precisely the components of the herbal medicine and the side effects of its use.
References
Abdel-Rahman, R. F., Soliman, G. A., Saeedan, A. S., Ogaly, H. A., Abd-Elsalam, R. M., Alqasoumi, S. I., & Abdel-Kader, M. S. (2019). Molecular and biochemical monitoring of the possible herb-drug interaction between Momordica charantia extract and glibenclamide in diabetic rats. Saudi Pharmaceutical Journal, 27 (6), 803-816.
Ali, A. M., Moqbel, M. S., & Al-Hizab, F. A. (2022). Effect of Momordica charantia on Insulin Immune-reactive Pancreatic Beta Cells and Blood Glucose Levels in Streptozotocin-induced Diabetic Rats. Indian Journal of Pharmaceutical Sciences, 84 (5), 438-445.
Aljohi, A., Matou-Nasri, S., Liu, D., Al-Khafaji, N., Slevin, M., & Ahmed, N. (2018). Momordica charantia extracts protect against inhibition of endothelial angiogenesis by advanced glycation endproducts in vitro. Food & function, 9(11), 5728-5739.
Arif, R., Ahmad, S., Mustafa, G., Mahrosh, H. S., Ali, M., Tahir ul Qamar, M., & Dar, H. R. (2021). Molecular docking and simulation studies of antidiabetic agents devised from hypoglycemic polypeptide-P of Momordica charantia. BioMed research international, 2021, 1-15.
Bahia, L., & Almeida-Pititto, B. (2023). Tratamento do diabetes mellitus tipo 2 no SUS. Diretriz Oficial da Sociedade Brasileira de Diabetes. 10.29327/5238993.2023-11.
Bai, W., Zhang, C., & Chen, H. (2018). Transcriptomic analysis of Momordica charantia polysaccharide on streptozotocin-induced diabetic rats. Gene, 675, 208-216.
Bhat, G. A., Khan, H. A., Alhomida, A. S., Sharma, P., Singh, R., & Paray, B. A. (2018). GLP-I secretion in healthy and diabetic Wistar rats in response to aqueous extract of Momordica charantia. BMC complementary and alternative medicine, 18 (162), 1-8.
Bortolotti, M., Mercatelli, D., & Polito, L. (2019). Momordica charantia, a nutraceutical approach for inflammatory related diseases. Frontiers in pharmacology, 10, 1-9.
Cobas, R., Rodacki, M., Giacaglia, L., Calliari, L., Noronha, R., Valerio, C., Custodio Jr, J.S., Scharf, M., Barcellos, C. R. G., Tomarchio, M. P., Silva, M. E. R., Santos, R. F., Zajdenverg, L., Gabbay, M. A. L, & Bertoluci, M. (2022). Diagnóstico do diabetes e rastreamento do diabetes tipo 2. Diretriz Oficial da Sociedade Brasileira de Diabetes, 557753-2022.
Chang, C. I., Cheng, S. Y., Nurlatifah, A. O., Sung, W. W., Tu, J. H., Lee, L. L., & Cheng, H. L. (2021). Bitter melon extract yields multiple effects on intestinal epithelial cells and likely contributes to anti-diabetic functions. International journal of medical sciences, 18 (8), 1848.
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. I. D. F. (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice, 138, 271-281.
Cortez-Navarrete, M., Martínez-Abundis, E., Pérez-Rubio, K. G., González-Ortiz, M., & Méndez-del Villar, M. (2018). Momordica charantia administration improves insulin secretion in type 2 diabetes mellitus. Journal of medicinal food, 21 (7), 672-677.
D'Almeida Filho, L. F., Bastos, J. L. A., de Medeiros Carlos, A., de Souza Lopes, E. H., Fachin, L. P., & Oliveira, E. C. T. (2022). O perfil epidemiológico da Diabetes Mellitus e estimativa da Retinopatia Diabética no Brasil, entre 2017 e 2021 The epidemiological profile of Diabetes Mellitus and estimates of Diabetic Retinopathy in Brazil, between 2017 and 2021. Brazilian Journal of Development, 8 (6), 46217-46225.
Elekofehinti, O. O., Oyedokun, V. O., Iwaloye, O., Lawal, A. O., & Ejelonu, O. C. (2021). Momordica charantia silver nanoparticles modulate S OCS/JAK/STAT and P13K/Akt/PTEN signalling pathways in the kidney of streptozotocin-induced diabetic rats. Journal of Diabetes & Metabolic Disorders, 20, 245-260.
Forouhi, N. G., & Wareham, N. J. (2019). Epidemiology of diabetes. Medicine, 47(1), 22-27.
Glovaci, D., Fan, W., & Wong, N. D. (2019). Epidemiology of diabetes mellitus and cardiovascular disease. Current cardiology reports, 21, 1-8.
Harreiter, J., & Roden, M. (2023). Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2023). Wiener Klinische Wochenschrift, 135(1), 7-17.
Hsu, P. K., Pan, F. F., & Hsieh, C. S. (2020). McIRBP-19 of bitter melon peptide effectively regulates diabetes mellitus (DM) patients’ blood sugar levels. Nutrients, 12 (5), 1252-1262.
Hussain, F., Hafeez, J., Khalifa, A. S., Naeem, M., Ali, T., & Eed, E. M. (2022). In vitro and in vivo study of inhibitory potentials of α-glucosidase and acetylcholinesterase and biochemical profiling of M. charantia in alloxan-induced diabetic rat models. American journal of translational research, 14 (6), 3824-3839.
Jiang, S., Xu, L., Xu, Y., Guo, Y., Wei, L., Li, X., & Song, W. (2020). Antidiabetic effect of Momordica charantia saponins in rats induced by high-fat diet combined with STZ. Electronic Journal of Biotechnology, 43, 41-47.
Keller, A. C., He, K., Brillantes, A. M., & Kennelly, E. J. (2021). A characterized saponin-rich fraction of Momordica charantia shows antidiabetic activity in C57BLK/6 mice fed a high fat diet. Phytomedicine Plus, 1 (4), 1-8.
Li, Z., Xia, A., Li, S., Yang, G., Jin, W., Zhang, M., & Wang, S. (2020). The pharmacological properties and therapeutic use of bitter melon (Momordica charantia L.). Current Pharmacology Reports, 6, 103-109.
Liu, J., Liu, Y., Sun, J., Guo, Y., Lei, Y., Guo, M., & Wang, L. (2023). Protective effects and mechanisms of Momordica charantia polysaccharide on early-stage diabetic retinopathy in type 1 diabetes. Biomedicine & Pharmacotherapy, 168 (115726), 1-14.
Lyra, R., Albuquerque, L., Cavalcanti, S., Tambascia, M., Valente, F., & Bertoluci, M. (2023). Tratamento Farmacológico da Hiperglicemia no DM2. Diretriz Oficial da Sociedade Brasileira de Diabetes. 10.29327/557753.2022-10.
Mahrosh, H. S., Mehmood, R., Bukhari, S. A., Afzal, G., & Arif, R. (2021). Investigation of hypoglycemic peptides derived from conserved regions of adMc1 to reveal their antidiabetic activities. BioMed Research International, 2021, 1-8.
Majeed, M., Majeed, A., Nagabhusahnam, K., Mundkur, L., & Paulose, S. (2021). A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin. Diabetology & Metabolic Syndrome, 13, 1-12.
Melo, K.F.S., Almeida-Pititto, B., & Pedrosa, H.C. (2023). Tratamento do Diabetes Mellitus Tipo 1 no SUS. Diretriz Oficial da Sociedade Brasileira de Diabetes. 10.29327/5238993.2023-12.
Murugesan, A., Yadav, S. K. R., & Dixit, A. (2022). Anti-hyperglycemic activity of HPLC-fractionated Momordica charantia seed extract enriched in a novel napin-like protein in experimental diabetic rats and its validation with recombinant napin-like protein. Current Research in Biotechnology, 4, 179-189.
Offor, U., Naidu, E. C., Ogedengbe, O. O., Aniekan, P. I., & Azu, O. O. (2020). Momordica charantia mitigates hepatic injury following adjuvant treatment with antiretroviral drugs in diabetic animal models. Toxicological Research, 36, 37-44.
Padhi, S., Nayak, A. K., & Behera, A. (2020). Type II diabetes mellitus: a review on recent drug based therapeutics. Biomedicine & Pharmacotherapy, 131, 1-23.
Perera, W. H., Shivanagoudra, S. R., Pérez, J. L., Kim, D. M., Sun, Y., K. Jayaprakasha, G., & Patil, B.S. (2021). Anti-inflammatory, antidiabetic properties and in silico modeling of cucurbitane-type triterpene glycosides from fruits of an Indian cultivar of Momordica charantia L. Molecules, 26 (4), 1038-1056.
Petersmann, A., Müller-Wieland, D., Müller, U. A., Landgraf, R., Nauck, M., Freckmann, G., Heinemann, L., & Schleicher, E. (2019). Definition, classification and diagnosis of diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes, 127 (1), 1-7.
Perumal, N., Nallappan, M., Shohaimi, S., Kassim, N. K., Tee, T. T., & Cheah, Y. H. (2022). Synergistic antidiabetic activity of Taraxacum officinale (L.) Weber ex FH Wigg and Momordica charantia L. polyherbal combination. Biomedicine & Pharmacotherapy, 145, 1-13.
Richter, E., Geetha, T., Burnett, D., Broderick, T. L., & Babu, J. R. (2023). The effects of Momordica charantia on type 2 diabetes mellitus and Alzheimer’s disease. International Journal of Molecular Sciences, 24 (5), 4643-4669.
Shimada, T., Kato, F., Dwijayanti, D. R., Nagata, T., Kinoshita, A., Okuyama, T., Nishizawa, M., & Mukai, E. (2022). Bitter melon fruit extract enhances intracellular ATP production and insulin secretion from rat pancreatic β-cells. British Journal of Nutrition, 127 (3), 377-383.
Shivanagoudra, S. R., Perera, W. H., Perez, J. L., Athrey, G., Sun, Y., Wu, C. S., Jayaprakasha, G. K., & Patil, B. S. (2019). In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L. Bioorganic & Medicinal Chemistry, 27 (14), 3097-3109.
Silva Júnior, W.S., Gabbay, M., Lamounier, R., & Bertoluci, M. (2023). Insulinoterapia no DM1. Diretriz Oficial da Sociedade Brasileira de Diabetes. 10.29327/557753.2022-5.
Souza, M. T. D., Silva, M. D. D., & Carvalho, R. D. (2010). Integrative review: what is it? How to do it? Einstein , 8, 102-106.
Sun, K., Ding, M., Fu, C., Li, P., Li, T., Fang, L., Xu, J., & Zhao, Y. (2023). Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats. Journal of Ethnopharmacology, 306, 116154, 1-10.
Tehseen, I., Haq, T. U., Ilahi, I., Khan, A. A., Attaullah, M., Zamani, G. Y., Zaman, S., & Ismail, I. (2022). Antidiabetic and hepato-renal protective effects of medicinal plants in STZ induced diabetic rats. Brazilian Journal of Biology, 84, 1-8.
Wang, Q., Wu, X., Shi, F., & Liu, Y. (2019). Comparison of antidiabetic effects of saponins and polysaccharides from Momordica charantia L. in STZ-induced type 2 diabetic mice. Biomedicine & Pharmacotherapy, 109, 744-750.
White, P. E., Król, E., Szwengiel, A., Tubacka, M., Szczepankiewicz, D., Staniek, H., Vincent, J. B., & Krejpcio, Z. (2021). Effects of bitter melon and a chromium propionate complex on symptoms of insulin resistance and type 2 diabetes in rat models. Biological trace element research, 199, 1013-1026.
Whittemore, R., & Knafl, K. (2005). The integrative review: updated methodology. Journal of advanced nursing, 52 (5), 546-553.
Zhang, C., Chen, H., & Bai, W. (2018). Characterization of Momordica charantia L. polysaccharide and its protective effect on pancreatic cells injury in STZ-induced diabetic mice. International journal of biological macromolecules, 115, 45-52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Emanuel Miguel Morais; Gabriel Augusto do Nascimento de Lucena Dourado; Gustavo Henrique de Freitas França; Izabella Caroline Vieira da Silva; Laura Guilhermina Cavalcante Alexandre; Luis Eduardo de Espíndola; Maria Emanuelly do Nascimento Cabral; Pedro Antônio Ferreira de Mendonça; Amanda Soares de Vasconcelos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
